comparemela.com
Home
Live Updates
PharmaEssentia Corporation: PharmaEssentia Selects Pint-Pharma as Commercial Partner for BESREMi (ropeginterferon alfa-2b-njft) in Latin America : comparemela.com
PharmaEssentia Corporation: PharmaEssentia Selects Pint-Pharma as Commercial Partner for BESREMi (ropeginterferon alfa-2b-njft) in Latin America
PharmaEssentia Corporation (TPEx:6446), a leading fully integrated biopharmaceutical company in Taiwan, today announced that it has entered into an exclusive license agreement with Pint-Pharma GmbH
Related Keywords
United States ,
Peru ,
Austria ,
Chile ,
Taipei ,
T Ai Pei ,
Taiwan ,
China ,
Mexico ,
South Korea ,
Brazil ,
Japan ,
Ecuador ,
Argentina ,
Colombia ,
America ,
Taiwanese ,
American ,
David Munoz ,
Pharma Gmb ,
Ko Chung Lin ,
Pharmaessentia Tpex ,
Meredith Manning ,
European Medicines Agency ,
Pharmaessentia Corporation Tpex ,
Pharmaessentia Corporation ,
Pint Pharma Gmbh ,
Latin America ,
Chief Executive Officer ,
South America ,
Polycythemia Vera ,
Prescribing Information ,
Private Securities Litigation Reform Act ,
Fibrotic Progression ,
Essential Thrombocythemia ,
Literature Review ,
Blood Cancer ,
Pharmaessentia ,
Corporation ,
Elects ,
Hint ,
Dharma ,
Commercial ,
Partner ,
Besremi ,
Ropeginterferon ,
Alfa ,
Jft ,
Satin ,
comparemela.com © 2020. All Rights Reserved.